Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multicenter, randomised, double-blind, placebo-controlled, phase 3 study to compare the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe uncontrolled asthma and elevated eosinophil levels

Trial Profile

A prospective, multicenter, randomised, double-blind, placebo-controlled, phase 3 study to compare the efficacy and the safety of masitinib versus placebo in the treatment of patients with severe uncontrolled asthma and elevated eosinophil levels

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Masitinib (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 01 Feb 2019 Status changed from recruiting to active, no longer recruiting.
    • 31 Aug 2017 According to an AB Science media release, the first patient has been recruited in this trial.
    • 31 Aug 2017 According to an AB Science media release, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top